Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) DOI: 10.1001/jamaneurol.2018.1212)

V. L. Stauffer, David William Dodick, Q. Zhang, J. N. Carter, J. Ailani, R. R. Conley

Research output: Contribution to journalComment/debate

Abstract

In the Original Investigation titled "Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial,"1 published online May 29, 2018, there was an error in Figure 1. In the bottom middle box, reflecting the number of patients who completed double-blind treatment in the galcanezumab 240-mg dose group, the percentage should read 82.5%. This article was corrected online.

Original languageEnglish (US)
Number of pages1
JournalJAMA Neurology
Volume75
Issue number9
DOIs
StatePublished - Sep 1 2018

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Erratum: Evaluation of galcanezumab for the prevention of episodic migraine: The EVOLVE-1 randomized clinical trial (JAMA Neurology (2018) DOI: 10.1001/jamaneurol.2018.1212)'. Together they form a unique fingerprint.

  • Cite this